The DOI matches its Crossref record; 112 of the 112 references it cites were found in a registry or an index.
Evolution of the SARS‐CoV‐2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission
Open accessAbstract
The first dominant SARS‐CoV‐2 Omicron variant BA.1 harbours 35 mutations in its Spike protein from the original SARS‐CoV‐2 variant that emerged late 2019. Soon after its discovery, BA.1 rapidly emerged to become the dominant variant worldwide and has since evolved into several variants. Omicron is of major public health concern owing to its high infectivity and antibody evasion. This review article examines the theories that have been proposed on the evolution of Omicron including zoonotic spillage, infection in immunocompromised individuals and cryptic spread in the community without being diagnosed. Added to the complexity of Omicron's evolution are the multiple reports of recombination events occurring between co‐circulating variants of Omicron with Delta and other variants such as XE. Current literature suggests that the combination of the novel mutations in Omicron has resulted in the variant having higher infectivity than the original Wuhan‐Hu‐1 and Delta variant. However, severity is believed to be less owing to the reduced syncytia formation and lower multiplication in the human lung tissue. Perhaps most challenging is that several studies indicate that the efficacy of the available vaccines have been reduced against Omicron variant (8–127 times reduction) as compared to the Wuhan‐Hu‐1 variant. The administration of booster vaccine, however, compensates with the reduction and improves the efficacy by 12–35 fold. Concerningly though, the broadly neutralising monoclonal antibodies, including those approved by FDA for therapeutic use against previous SARS‐CoV‐2 variants, are mostly ineffective against Omicron with the exception of Sotrovimab and recent reports suggest that the Omicron BA.2 is also resistant to Sotrovimab. Currently two new Omicron variants BA.4 and BA.5 are emerging and are reported to be more transmissible and resistant to immunity generated by previous variants including Omicron BA.1 and most monoclonal antibodies. As new variants of SARS‐CoV‐2 will likely continue to emerge it is important that the evolution, and biological consequences of new mutations, in existing variants be well understood.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grifoni, A., Weiskopf, D., Ramirez, S. I., Mateus, J., Dan, J. M., Moderbacher, C. R., Rawlings, S. A., Sutherland, A., Premkumar, L., Jadi, R. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.015 · Cited by 3,595
Nextstrain: real-time tracking of pathogen evolution
Hadfield, J., Megill, C., Bell, S. M., Huddleston, J., Potter, B., Callender, C., Sagulenko, P., Bedford, T., & Neher, R. A. (2018) · Bioinformatics · doi:10.1093/bioinformatics/bty407 · Cited by 3,154
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885
Adaptive immunity to SARS-CoV-2 and COVID-19
Sette, A., & Crotty, S. (2021) · Cell · doi:10.1016/j.cell.2021.01.007 · Cited by 1,860
Rydyznski Moderbacher, C., Ramirez, S. I., Dan, J. M., Grifoni, A., Hastie, K. M., Weiskopf, D., Belanger, S., Abbott, R. K., Kim, C., Choi, J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.038 · Cited by 1,790
Structural and functional analysis of a potent sarbecovirus neutralizing antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · doi:10.1101/2020.04.07.023903 · Cited by 1,752
Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months
Levin, E. G., Lustig, Y., Cohen, C., Fluss, R., Indenbaum, V., Amit, S., Doolman, R., Asraf, K., Mendelson, E., Ziv, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114583 · Cited by 1,703
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Viana, R., Moyo, S., Amoako, D. G., Tegally, H., Scheepers, C., Althaus, C. L., Anyaneji, U. J., Bester, P. A., Boni, M. F., Chand, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04411-y · Cited by 1,690
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514
A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2
Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., Zhang, Z., Fan, P., Dong, Y., Yang, Y., et al. (2020) · Science · doi:10.1126/science.abc6952 · Cited by 1,385
BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et al. (2022) · Nature · doi:10.1038/s41586-022-04980-y · Cited by 1,335
Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer, D., Scheepers, C., Amoako, D., et al. (2021) · doi:10.1101/2021.12.08.21267417 · Cited by 1,333
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host
Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo, H.-H., Boucau, J., Bowman, K., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2031364 · Cited by 1,246
Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic
Karim, S. S. A., & Karim, Q. A. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02758-6 · Cited by 1,226
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., De Marco, A., di Iulio, J., et al. (2022) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,080
Viral targets for vaccines against COVID-19
Dai, L., & Gao, G. F. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00480-0 · Cited by 1,048
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant
Garcia-Beltran, W. F., St. Denis, K. J., Hoelzemer, A., Lam, E. C., Nitido, A. D., Sheehan, M. L., Berrios, C., Ofoman, O., Chang, C. C., Hauser, B. M., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.033 · Cited by 1,045
Wolter, N., Jassat, W., Walaza, S., Welch, R., Moultrie, H., Groome, M., Amoako, D. G., Everatt, J., Bhiman, J. N., Scheepers, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00017-4 · Cited by 1,041
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Dejnirattisai, W., Huo, J., Zhou, D., Zahradník, J., Supasa, P., Liu, C., Duyvesteyn, H. M. E., Ginn, H. M., Mentzer, A. J., Tuekprakhon, A., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.046 · Cited by 930 · cited 12×
“Omicron causes widespread escape from neutralisation by serum obtained following infection by a range of SARS‐CoV‐2 variants, meaning that previously infected individuals will have little protection from infection with Omicron.(13) In recent research, investigators studied the neutralisation capacity of the Omicron BA.”
BackgroundInfluentialAraf, Y., Akter, F., Tang, Y., Fatemi, R., Parvez, M. S. A., Zheng, C., & Hossain, M. G. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27588 · Cited by 862
Menni, C., Valdes, A. M., Polidori, L., Antonelli, M., Penamakuri, S., Nogal, A., Louca, P., May, A., Figueiredo, J. C., Hu, C., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00327-0 · Cited by 854
Antibody evasion properties of SARS-CoV-2 Omicron sublineages
Iketani, S., Liu, L., Guo, Y., Liu, L., Chan, J. F.-W., Huang, Y., Wang, M., Luo, Y., Yu, J., Chu, H., et al. (2022) · Nature · doi:10.1038/s41586-022-04594-4 · Cited by 809
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795
VanBlargan, L. A., Errico, J. M., Halfmann, P. J., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. S. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 705
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., Duyvesteyn, H. M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.005 · Cited by 686
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669
Omicron Variant (B.1.1.529): Infectivity, Vaccine Breakthrough, and Antibody Resistance
Chen, J., Wang, R., Gilby, N. B., & Wei, G.-W. (2022) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c01451 · Cited by 653
Accorsi, E. K., Britton, A., Fleming-Dutra, K. E., Smith, Z. R., Shang, N., Derado, G., Miller, J., Schrag, S. J., & Verani, J. R. (2022) · JAMA · doi:10.1001/jama.2022.0470 · Cited by 628
A Bivalent Omicron-Containing Booster Vaccine against Covid-19
Chalkias, S., Harper, C., Vrbicky, K., Walsh, S. R., Essink, B., Brosz, A., McGhee, N., Tomassini, J. E., Chen, X., Chang, Y., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2208343 · Cited by 627
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590
Neutralization Escape by SARS-CoV-2 Omicron Subvariants BA.2.12.1, BA.4, and BA.5
Hachmann, N. P., Miller, J., Collier, A.-R. Y., Ventura, J. D., Yu, J., Rowe, M., Bondzie, E. A., Powers, O., Surve, N., Hall, K., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206576 · Cited by 550
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., et al. (2022) · Science · doi:10.1126/science.abn8652 · Cited by 535
Geers, D., Shamier, M. C., Bogers, S., den Hartog, G., Gommers, L., Nieuwkoop, N. N., Schmitz, K. S., Rijsbergen, L. C., van Osch, J. A. T., Dijkhuizen, E., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abj1750 · Cited by 529
SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution
Zahradník, J., Marciano, S., Shemesh, M., Zoler, E., Harari, D., Chiaravalli, J., Meyer, B., Rudich, Y., Li, C., Marton, I., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00954-4 · Cited by 457
SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination
Pajon, R., Doria-Rose, N. A., Shen, X., Schmidt, S. D., O’Dell, S., McDanal, C., Feng, W., Tong, J., Eaton, A., Maglinao, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119912 · Cited by 457
Recombination in viruses: Mechanisms, methods of study, and evolutionary consequences
Pérez-Losada, M., Arenas, M., Galán, J. C., Palero, F., & González-Candelas, F. (2015) · Infection, Genetics and Evolution · doi:10.1016/j.meegid.2014.12.022 · Cited by 450
Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
Altarawneh, H. N., Chemaitelly, H., Hasan, M. R., Ayoub, H. H., Qassim, S., AlMukdad, S., Coyle, P., Yassine, H. M., Al-Khatib, H. A., Benslimane, F. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2200133 · Cited by 445
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and Monoclonal Antibodies
Wilhelm, A., Widera, M., Grikscheit, K., Toptan, T., Schenk, B., Pallas, C., Metzler, M., Kohmer, N., Hoehl, S., Helfritz, F. A., et al. (2021) · doi:10.1101/2021.12.07.21267432 · Cited by 440
Plasma Neutralization of the SARS-CoV-2 Omicron Variant
Schmidt, F., Muecksch, F., Weisblum, Y., Da Silva, J., Bednarski, E., Cho, A., Wang, Z., Gaebler, C., Caskey, M., Nussenzweig, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119641 · Cited by 432
Third BNT162b2 Vaccination Neutralization of SARS-CoV-2 Omicron Infection
Nemet, I., Kliker, L., Lustig, Y., Zuckerman, N., Erster, O., Cohen, C., Kreiss, Y., Alroy-Preis, S., Regev-Yochay, G., Mendelson, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119358 · Cited by 418
Gruell, H., Vanshylla, K., Tober-Lau, P., Hillus, D., Schommers, P., Lehmann, C., Kurth, F., Sander, L. E., & Klein, F. (2022) · Nature Medicine · doi:10.1038/s41591-021-01676-0 · Cited by 410
Ancestral SARS-CoV-2-specific T cells cross-recognize the Omicron variant
Gao, Y., Cai, C., Grifoni, A., Müller, T. R., Niessl, J., Olofsson, A., Humbert, M., Hansson, L., Österborg, A., Bergman, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01700-x · Cited by 403
Lewnard, J. A., Hong, V. X., Patel, M. M., Kahn, R., Lipsitch, M., & Tartof, S. Y. (2022) · Nature Medicine · doi:10.1038/s41591-022-01887-z · Cited by 390
Efficacy of a Fourth Dose of Covid-19 mRNA Vaccine against Omicron
Regev-Yochay, G., Gonen, T., Gilboa, M., Mandelboim, M., Indenbaum, V., Amit, S., Meltzer, L., Asraf, K., Cohen, C., Fluss, R., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2202542 · Cited by 386
Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant
Takashita, E., Kinoshita, N., Yamayoshi, S., Sakai-Tagawa, Y., Fujisaki, S., Ito, M., Iwatsuki-Horimoto, K., Chiba, S., Halfmann, P., Nagai, H., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2119407 · Cited by 376
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
(2022) · doi:10.1056/nejmoa2201570 · Cited by 376
Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera
Muik, A., Lui, B. G., Wallisch, A.-K., Bacher, M., Mühl, J., Reinholz, J., Ozhelvaci, O., Beckmann, N., Güimil Garcia, R. D. L. C., Poran, A., et al. (2022) · Science · doi:10.1126/science.abn7591 · Cited by 367
Population Immunity and Covid-19 Severity with Omicron Variant in South Africa
Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A. J., Blumberg, L., Welch, R., Ngorima-Mabhena, N., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119658 · Cited by 366
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum
Dejnirattisai, W., Shaw, R. H., Supasa, P., Liu, C., Stuart, A. S., Pollard, A. J., Liu, X., Lambe, T., Crook, D., Stuart, D. I., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(21)02844-0 · Cited by 339
Immune boosting by B.1.1.529 ( Omicron) depends on previous SARS-CoV-2 exposure
Reynolds, C. J., Pade, C., Gibbons, J. M., Otter, A. D., Lin, K.-M., Muñoz Sandoval, D., Pieper, F. P., Butler, D. K., Liu, S., Joy, G., et al. (2022) · Science · doi:10.1126/science.abq1841 · Cited by 337
Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants
Yu, J., Collier, A.-R. Y., Rowe, M., Mardas, F., Ventura, J. D., Wan, H., Miller, J., Powers, O., Chung, B., Siamatu, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2201849 · Cited by 326
The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic
Otto, S. P., Day, T., Arino, J., Colijn, C., Dushoff, J., Li, M., Mechai, S., Van Domselaar, G., Wu, J., Earn, D. J. D., et al. (2021) · Current Biology · doi:10.1016/j.cub.2021.06.049 · Cited by 323
Estimates of SARS-CoV-2 Omicron Variant Severity in Ontario, Canada
Ulloa, A. C., Buchan, S. A., Daneman, N., & Brown, K. A. (2022) · JAMA · doi:10.1001/jama.2022.2274 · Cited by 316
Xia, S., Lan, Q., Su, S., Wang, X., Xu, W., Liu, Z., Zhu, Y., Wang, Q., Lu, L., & Jiang, S. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0184-0 · Cited by 312
Evidence for a mouse origin of the SARS-CoV-2 Omicron variant
Wei, C., Shan, K.-J., Wang, W., Zhang, S., Huan, Q., & Qian, W. (2021) · Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.12.003 · Cited by 288
Bruel, T., Hadjadj, J., Maes, P., Planas, D., Seve, A., Staropoli, I., Guivel-Benhassine, F., Porrot, F., Bolland, W.-H., Nguyen, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01792-5 · Cited by 282
The Middle East Respiratory Syndrome (MERS)
Azhar, E. I., Hui, D. S. C., Memish, Z. A., Drosten, C., & Zumla, A. (2019) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2019.08.001 · Cited by 278
Household transmission of the SARS-CoV-2 Omicron variant in Denmark
Lyngse, F. P., Mortensen, L. H., Denwood, M. J., Christiansen, L. E., Møller, C. H., Skov, R. L., Spiess, K., Fomsgaard, A., Lassaunière, R., Rasmussen, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33328-3 · Cited by 255
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/d41586-021-03825-4 · Cited by 254
Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic
Jackson, B., Boni, M. F., Bull, M. J., Colleran, A., Colquhoun, R. M., Darby, A. C., Haldenby, S., Hill, V., Lucaci, A., McCrone, J. T., et al. (2021) · Cell · doi:10.1016/j.cell.2021.08.014 · Cited by 238
Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
Khan, K., Karim, F., Ganga, Y., Bernstein, M., Jule, Z., Reedoy, K., Cele, S., Lustig, G., Amoako, D., Wolter, N., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32396-9 · Cited by 230
Edara, V.-V., Manning, K. E., Ellis, M., Lai, L., Moore, K. M., Foster, S. L., Floyd, K., Davis-Gardner, M. E., Mantus, G., Nyhoff, L. E., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100529 · Cited by 213
Ou, J., Lan, W., Wu, X., Zhao, T., Duan, B., Yang, P., Ren, Y., Quan, L., Zhao, W., Seto, D., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00992-2 · Cited by 212
Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater
Smyth, D. S., Trujillo, M., Gregory, D. A., Cheung, K., Gao, A., Graham, M., Guan, Y., Guldenpfennig, C., Hoxie, I., Kannoly, S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28246-3 · Cited by 210
Jassat, W., Abdool Karim, S. S., Mudara, C., Welch, R., Ozougwu, L., Groome, M. J., Govender, N., von Gottberg, A., Wolter, N., Wolmarans, M., et al. (2022) · The Lancet Global Health · doi:10.1016/s2214-109x(22)00114-0 · Cited by 202
Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies
Yamasoba, D., Kosugi, Y., Kimura, I., Fujita, S., Uriu, K., Ito, J., & Sato, K. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00365-6 · Cited by 202
Neutralization of the SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants
Qu, P., Faraone, J., Evans, J. P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J. S., Lozanski, G., Mallampalli, R. K., Saif, L. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmc2206725 · Cited by 161
Where did ‘weird’ Omicron come from?
Kupferschmidt, K. (2021) · Science · doi:10.1126/science.acx9738 · Cited by 154 · cited 10×
“Phylogenetic analysis of global SARS‐CoV‐2 sequences has not revealed any close intermediary sequences between Omicron and its closest relatives, therefore the pathway to the emergence of Omicron is unclear.30 The evolu- tionary analysis did not reveal any special mutational profile or frameshift event that could sugg…”
BackgroundInfluentialAggarwal, A., Akerman, A., Milogiannakis, V., Silva, M. R., Walker, G. J., Stella, A. O., Kindinger, A., Angelovich, T. A., Waring, E., Amatayakul‐Chantler, S., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104270 · Cited by 152
Self-citationWhere did Omicron come from? Three key theories
Mallapaty, S. (2022) · Nature · doi:10.1038/d41586-022-00215-2 · Cited by 150
Furin cleavage of the SARS-CoV-2 spike is modulated by O -glycosylation
Zhang, L., Mann, M. D., Syed, Z. A., Reynolds, H. M., Tian, E., Samara, N. L., Zeldin, D. C., Tabak, L. A., & Hagen, K. G. T. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2109905118 · Cited by 143
Davies, M., Kassanjee, R., Rousseau, P., Morden, E., Johnson, L. F., Solomon, W., Hsiao, M., Hussey, H. S., Meintjes, G., Paleker, M., et al. (2022) · Tropical Medicine & International Health · doi:10.1111/tmi.13752 · Cited by 138
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants
Reynolds, C. J., Gibbons, J. M., Pade, C., Lin, K., Sandoval, D. M., Pieper, F. P., Butler, D. K., Liu, S., Otter, A. D., Joy, G., et al. (2022) · Science · doi:10.1126/science.abm0811 · Cited by 130
How severe are Omicron infections?
Ledford, H. K. (2021) · Nature · doi:10.1038/d41586-021-03794-8 · Cited by 127
Origin and evolutionary analysis of the SARS-CoV-2 Omicron variant
Sun, Y., Lin, W., Dong, W., & Xu, J. (2021) · Journal of Biosafety and Biosecurity · doi:10.1016/j.jobb.2021.12.001 · Cited by 123
Braun, K. M., Moreno, G. K., Wagner, C., Accola, M. A., Rehrauer, W. M., Baker, D., Koelle, K., O’Connor, D. H., Bedford, T., Friedrich, T. C., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009849 · Cited by 120
Aggarwal, A., Stella, A. O., Walker, G. J., Akerman, A., Esneau, C., Milogiannakis, V., Burnett, D. L., McAllery, S., Silva, M. R., Lu, Y., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01135-7 · Cited by 120
Self-citationZhou, H., Tada, T., Dcosta, B. M., & Landau, N. R. (2022) · Viruses · doi:10.3390/v14061334 · Cited by 108
Poudel, S., Ishak, A., Pérez-Fernández, J., Garcia, E., León‐Figueroa, D. A., Romaní, L., Bonilla‐Aldana, D. K., & Rodriguez-Morales, A. J. (2021) · Travel Medicine and Infectious Disease · doi:10.1016/j.tmaid.2021.102234 · Cited by 107
Persistent SARS-CoV-2 infection and intra-host evolution in association with advanced HIV infectionPreprint
Karim, F., Moosa, M.-Y. S., Gosnell, B., Cele, S., Giandhari, J., Pillay, S., Tegally, H., Wilkinson, E., San, J., Msomi, N., et al. (2021) · medRxiv · doi:10.1101/2021.06.03.21258228 · Cited by 106
Nussenblatt, V. R., Roder, A. E., Das, S. B., de Wit, E., Youn, J.-H., Banakis, S., Mushegian, A. A., Mederos, C., Wang, W., Chung, M. C., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab622 · Cited by 101
COVID‐19 severity from Omicron and Delta SARS‐CoV‐2 variants
Wrenn, J. O., Pakala, S. B., Vestal, G., Shilts, M. H., Brown, H. M., Bowen, S. M., Strickland, B. A., Williams, T., Mallal, S. A., Jones, I. D., et al. (2022) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12982 · Cited by 99
Yu, X., Wei, D., Xu, W., Li, Y., Li, X., Zhang, X., Qu, J., Yang, Z., & Chen, E. (2022) · Cell Discovery · doi:10.1038/s41421-022-00375-5 · Cited by 95
Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3
Arora, P., Zhang, L., Rocha, C., Sidarovich, A., Kempf, A. M., Schulz, S. R., Cossmann, A., Manger, B., Baier, E., Tampe, B., et al. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00224-9 · Cited by 95
Redd, A. D., Nardin, A., Kared, H., Bloch, E. M., Abel, B., Pekosz, A. S., Laeyendecker, O. B., Fehlings, M., Quinn, T. C., & Tobian, A. A. R. (2022) · mBio · doi:10.1128/mbio.03617-21 · Cited by 93
Bentley, E. G., Kirby, A., Sharma, P., Kipar, A., Mega, D. F., Bramwell, C., Penrice-Randal, R., Prince, T., Brown, J. C., Zhou, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.26.474085 · Cited by 91
Antibody Response and Variant Cross-Neutralization After SARS-CoV-2 Breakthrough Infection
Bates, T. A., McBride, S. K., Winders, B., Schoen, D., Trautmann, L., Curlin, M. E., & Tafesse, F. (2021) · JAMA · doi:10.1001/jama.2021.22898 · Cited by 91
Evidence for SARS-CoV-2 Delta and Omicron Coinfections and Recombination
Bolze, A., Basler, T., White, S. J., Rossi, A. D., Wyman, D., Dai, H., Roychoudhury, P., Greninger, A. L., Hayashibara, K. C., Beatty, M. E., et al. (2022) · Med · doi:10.1016/j.medj.2022.10.002 · Cited by 88
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2022) · Viruses · doi:10.3390/v14010079 · Cited by 82
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
Shrestha, L. B., Tedla, N. T., & Bull, R. A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752003 · Cited by 78
Self-citationColson, P., Fournier, P., Delerce, J., Million, M., Bedotto, M., Houhamdi, L., Yahi, N., Bayette, J., Levasseur, A., Fantini, J., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27789 · Cited by 77
Gesesew, H. A., Koye, D. N., Fetene, D. M., Woldegiorgis, M. A., Kinfu, Y., Geleto, A. B., Melaku, Y. A., Mohammed, H., Alene, K. A., Awoke, M. A., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-044618 · Cited by 75
Lee, I., Sun, C., Wu, P., Lan, Y.-H., Wang, I.-H., Liu, W., Yuan, J. P., Chang, Y.-W., Tseng, S.-C., Tsung, S.-I., et al. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00830-1 · Cited by 69
Effects of Environmental Factors on Severity and Mortality of COVID-19
Kifer, D., Bugada, D., Villar-García, J., Gudelj, I., Menni, C., Sudre, C. H., Vučković, F., Ugrina, I., Lorini, F. L., Posso, M., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2020.607786 · Cited by 68
One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages
Gónzález‐Candelas, F., Shaw, M., Phan, T. G., Kulkarni‐Kale, U., Paraskevis, D. N., Luciani, F., Kimura, H., & Sironi, M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104869 · Cited by 68
Tiecco, G., Storti, S., Antoni, M. D., Focà, E., Castelli, F., & Quirós-Roldán, E. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23041987 · Cited by 59
SARS-CoV-2 Evolution: On the Sudden Appearance of the Omicron Variant
Berkhout, B., & Herrera-Carrillo, E. (2022) · Journal of Virology · doi:10.1128/jvi.00090-22 · Cited by 57
A meta-analysis of Early Results to predict Vaccine efficacy against OmicronPreprint
Khoury, D. S., Steain, M. C., Triccas, J. A., Sigal, A., Davenport, M. P., & Cromer, D. (2021) · medRxiv · doi:10.1101/2021.12.13.21267748 · Cited by 51
Balachandran, H., Phetsouphanh, C., Agapiou, D., Adhikari, A., Rodrigo, C., Hammoud, M., Shrestha, L. B., Keoshkerian, E., Gupta, M., Turville, S. G., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110345 · Cited by 49
Self-citationBurnett, D. L., Jackson, K., Langley, D. B., Aggarwal, A., Stella, A. O., Johansen, M. D., Balachandran, H., Lenthall, H., Rouet, R., Walker, G. J., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.019 · Cited by 45
Self-citationHaveri, A., Solastie, A., Ekström, N., Österlund, P., Nohynek, H., Nieminen, T. A., PALMU, A. A. I., & Melin, M. M. (2022) · European Journal of Immunology · doi:10.1002/eji.202149785 · Cited by 41
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
Rouet, R., Mazigi, O., Walker, G. J., Langley, D. B., Sobti, M., Schofield, P., Lenthall, H., Jackson, J., Ubiparipovic, S., Henry, J. Y., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1922134 · Cited by 36
Self-citationReactive T Cells in Convalescent COVID-19 Patients With Negative SARS-CoV-2 Antibody Serology
Steiner, S., Schwarz, T., Corman, V. M., Sotzny, F., Bauer, S., Drosten, C., Volk, H., Scheibenbogen, C., & Hanitsch, L. G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687449 · Cited by 29
Identification of a Novel SARS-CoV-2 Delta-Omicron Recombinant Virus in the United StatesPreprint
Lacek, K. A., Rambo‐Martin, B. L., Batra, D. G., Zheng, X.-Y., Sakaguchi, H., Peacock, T. P., Keller, M. W., Wilson, M. M., Sheth, M., Davis, M. L., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.19.484981 · Cited by 28
Vaccine booster efficiently inhibits entry of SARS-CoV-2 omicron variant
Zhang, W., Huang, L., Ye, G., Geng, Q., Ikeogu, N., Harris, M., Dileepan, G., Burrack, K. S., Du, L., Frosch, A. E. P., et al. (2022) · Cellular and Molecular Immunology · doi:10.1038/s41423-022-00837-6 · Cited by 25
Wu, J., Nie, J., Zhang, L., Song, H., An, Y., Liang, Z., Yang, J., Ding, R., Liu, S., Li, Q., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00874-7 · Cited by 18
Factors affecting aerosol SARS-CoV-2 transmission via HVAC systems; a modeling study
Cotman, Z. J., Bowden, M. J., Richter, B. P., Phelps, J. H., & Dibble, C. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009474 · Cited by 17
García‐Vidal, C., Iglesias‐Caballero, M., Puerta‐Alcalde, P., Más, V., Cuesta, G., García-Pouton, N., Varona, S., Pozo, F., Vázquez‐Morón, S., Marcos, M. Á., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.826883 · Cited by 14
Strasser, Z. H., Hadavand, A., Murphy, S. N., & Estiri, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1601788/v1 · Cited by 13
Influenza and Other Respiratory Viruses
Yoshikawa, T. T., & Ouslander, J. G. (2002) · CRC Press eBooks · doi:10.1201/9780824744311-19 · Cited by 13
SARS-CoV-2 T cell responses are expected to remain robust against OmicronPreprint
Ahmed, S. F., Quadeer, A. A., & McKay, M. R. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.12.472315 · Cited by 12
Cited by
(2024) · doi:10.1038/s41467-024-50286-0 · Cited by 9
Mandolesi, M., Das, H., de Vries, L., Yang, Y., Kim, C., Dhinakaran, M., Dopico, X. C., Fischbach, J., Kim, S., Guryleva, M., et al. (2024) · doi:10.21203/rs.3.rs-3958951/v1 · Cited by 2
Metadata
- Authors
- Shrestha, L. B., Foster, C., Rawlinson, W., Tedla, N., & Bull, R. A.
- Venue
- Reviews in Medical Virology
- Publisher
- Wiley
- Published
- 2022-07-20
- Volume
- 32
- Issue
- 5
- Pages
- e2381-e2381
- ISSN
- 1052-9276 (ISSN-L)
- 1099-1654
- OpenAlex
- W4285993171
- Cited by
- 474
- References
- 112
- FWCI
- 50.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.